{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:24:49Z","timestamp":1788312289629,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003052","name":"Ministry of Trade, Industry and Energy","doi-asserted-by":"publisher","award":["RS-2024-00448560"],"award-info":[{"award-number":["RS-2024-00448560"]}],"id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013129","name":"Ministry of SMEs and Startups","doi-asserted-by":"publisher","award":["RS-2025-25465822"],"award-info":[{"award-number":["RS-2025-25465822"]}],"id":[{"id":"10.13039\/501100013129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["2025-rise-15-105"],"award-info":[{"award-number":["2025-rise-15-105"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cardiotoxicity remains the leading driver of drug attrition; however, its prediction remains suboptimal when conventional hERG assays and animal models are used. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) offer a human-relevant alternative that aligns with the CiPA initiative and ICH E14\/S7B guidelines. This study validated an integrated platform that combines high-purity hiPSC-CMs with Artificial Intelligence (AI) to enhance the accuracy of predicting drug-induced proarrhythmic risk. Phenotypic characterization of the hiPSC-CMs demonstrated high cardiac differentiation efficiency (cTnT\u2009+\u2009\u2009&gt;\u200995%) and a predominant ventricular-like identity (MLC-2\u00a0V\u2009+\u2009, 78\u201384%), ensuring biological relevance for ventricular arrhythmia assessment. Electrophysiological data from 28 CiPA reference compounds were collected via Multielectrode Array (MEA) to train multiple machine learning models. The Artificial Neural Network outperformed the other architectures, achieving a superior ROC-AUC of 0.982. The utility of the platform was evaluated using 12 anticancer agents. Although most drugs showed dose-dependent reductions in impedance-based viability, four compounds (Idarubicin, Erlotinib, Sunitinib, Cyclophosphamide) did not exhibit overt structural cytotoxicity. However, MEA analysis revealed significant functional perturbations, including FPDcF prolongation, in sunitinib- and erlotinib-treated samples after long-term treatment. The AI model subsequently classified these two agents as high-to-intermediate risk for Torsades de Pointes (TdP), thereby quantifying their time-dependent proarrhythmic liabilities. These findings show the platform\u2019s ability to detect hidden functional cardiotoxicity, often missed by standard viability assays. The AI-hiPSC-CM system offers a high-throughput, early-stage safety screening tool that bridges in vitro data and clinical outcomes with a standardized risk assessment framework.<\/jats:p>","DOI":"10.1007\/s00204-026-04361-8","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:48:45Z","timestamp":1777402125000},"page":"3553-3565","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrating high-fidelity hiPSC-cardiomyocytes with AI-driven modeling for enhanced proarrhythmic risk assessment"],"prefix":"10.1007","volume":"100","author":[{"given":"Su-Bin","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaehun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieun","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ara","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwan","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choongseong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Adnan","family":"Pramudito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Moo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7470-018X","authenticated-orcid":false,"given":"Dong-Hun","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"4361_CR1","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1200\/JCO.1995.13.11.2827","volume":"13","author":"P Anderlini","year":"1995","unstructured":"Anderlini P, Benjamin RS, Wong FC et al (1995) Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 13:2827\u20132834. https:\/\/doi.org\/10.1200\/JCO.1995.13.11.2827","journal-title":"J Clin Oncol"},{"key":"4361_CR2","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1016\/j.celrep.2018.08.079","volume":"24","author":"K Blinova","year":"2018","unstructured":"Blinova K, Dang Q, Millard D et al (2018) International multisite study of human-induced pluripotent stem cell-derived cardiomyocytes for drug proarrhythmic potential assessment. Cell Rep 24:3582\u20133592. https:\/\/doi.org\/10.1016\/j.celrep.2018.08.079","journal-title":"Cell Rep"},{"key":"4361_CR3","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1155\/2021\/8863789","volume":"2021","author":"R Carrasco","year":"2021","unstructured":"Carrasco R, Castillo RL, Gormaz JG et al (2021) Role of oxidative stress in the mechanisms of anthracycline-induced cardiotoxicity: effects of preventive strategies. Oxid Med Cell Longev 2021:3789. https:\/\/doi.org\/10.1155\/2021\/8863789","journal-title":"Oxid Med Cell Longev"},{"key":"4361_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1137983","author":"SHY Chan","year":"2023","unstructured":"Chan SHY, Khatib Y, Webley S et al (2023) Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: a systematic review. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2023.1137983","journal-title":"Front Pharmacol"},{"key":"4361_CR5","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","volume":"370","author":"TF Chu","year":"2007","unstructured":"Chu TF, Rupnick MA, Kerkela R et al (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011\u20132019. https:\/\/doi.org\/10.1016\/S0140-6736(07)61865-0","journal-title":"Lancet"},{"key":"4361_CR6","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1200\/JCO.2015.61.5187","volume":"33","author":"EAM Feijen","year":"2015","unstructured":"Feijen EAM, Leisenring WM, Stratton KL et al (2015) Equivalence ratio for daunorubicin to doxorubicin in relation to late heart failure in survivors of childhood cancer. J Clin Oncol 33:3774\u20133780. https:\/\/doi.org\/10.1200\/JCO.2015.61.5187","journal-title":"J Clin Oncol"},{"key":"4361_CR7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.pharmthera.2008.04.010","volume":"119","author":"GA Gintant","year":"2008","unstructured":"Gintant GA (2008) Preclinical torsades-de-pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk. Pharmacol Ther 119:199\u2013209. https:\/\/doi.org\/10.1016\/j.pharmthera.2008.04.010","journal-title":"Pharmacol Ther"},{"key":"4361_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1109\/JTEHM.2019.2907945","volume":"7","author":"Z Golgooni","year":"2019","unstructured":"Golgooni Z, Mirsadeghi S, Baghshah MS et al (2019) Deep learning-based proarrhythmia analysis using field potentials recorded from human pluripotent stem cells derived cardiomyocytes. IEEE J Transl Eng Health Med 7:1\u20139. https:\/\/doi.org\/10.1109\/JTEHM.2019.2907945","journal-title":"IEEE J Transl Eng Health Med"},{"key":"4361_CR9","doi-asserted-by":"publisher","first-page":"H12","DOI":"10.1152\/ajpheart.00631.2023","volume":"327","author":"D Guerrelli","year":"2024","unstructured":"Guerrelli D, Pressman J, Salameh S, Posnack N (2024) hiPSC-CM electrophysiology: impact of temporal changes and study parameters on experimental reproducibility. Am J Physiol Heart Circ Physiol 327:H12\u2013H27. https:\/\/doi.org\/10.1152\/ajpheart.00631.2023","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"4361_CR10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.cotox.2020.07.004","volume":"23\u201324","author":"RL Hamlin","year":"2020","unstructured":"Hamlin RL, Keene BW (2020) Species differences in cardiovascular physiology that affect pharmacology and toxicology. Curr Opin Toxicol 23\u201324:106\u2013113. https:\/\/doi.org\/10.1016\/j.cotox.2020.07.004","journal-title":"Curr Opin Toxicol"},{"key":"4361_CR11","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/toxsci\/kft113","volume":"134","author":"K Harris","year":"2013","unstructured":"Harris K, Aylott M, Cui Y et al (2013) Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. Toxicol Sci 134:412\u2013426. https:\/\/doi.org\/10.1093\/toxsci\/kft113","journal-title":"Toxicol Sci"},{"key":"4361_CR12","doi-asserted-by":"publisher","first-page":"13807","DOI":"10.1097\/MD.0000000000013807","volume":"97","author":"Y Hu","year":"2018","unstructured":"Hu Y, Sun B, Zhao B et al (2018) Cisplatin-induced cardiotoxicity with midrange ejection fraction: a case report and review of the literature. Medicine (United States) 97:13807. https:\/\/doi.org\/10.1097\/MD.0000000000013807","journal-title":"Medicine (United States)"},{"key":"4361_CR13","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1080\/14728222.2016.1250887","volume":"20","author":"S Jiang","year":"2016","unstructured":"Jiang S, Yang Y, Li T et al (2016) An overview of the mechanisms and novel roles of Nrf2 in cardiovascular diseases. Expert Opin Ther Targets 20:1413\u20131424. https:\/\/doi.org\/10.1080\/14728222.2016.1250887","journal-title":"Expert Opin Ther Targets"},{"key":"4361_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1752-8062.2008.00090.x","volume":"2","author":"R Kerkela","year":"2009","unstructured":"Kerkela R, Woulfe KC, Durand JB et al (2009) Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci 2:15\u201325. https:\/\/doi.org\/10.1111\/j.1752-8062.2008.00090.x","journal-title":"Clin Transl Sci"},{"key":"4361_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2024.1308217","volume":"15","author":"TYT Lee","year":"2024","unstructured":"Lee TYT, Coles JG, Maynes JT (2024) iPSC-cardiomyocytes in the preclinical prediction of candidate pharmaceutical toxicity. Front Pharmacol 15:1\u201315. https:\/\/doi.org\/10.3389\/fphar.2024.1308217","journal-title":"Front Pharmacol"},{"key":"4361_CR16","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s00018-016-2407-7","volume":"74","author":"T Li","year":"2017","unstructured":"Li T, Jiang S, Yang Z et al (2017) Targeting the energy guardian AMPK: another avenue for treating cardiomyopathy? Cell Mol Life Sci 74:1413\u20131429. https:\/\/doi.org\/10.1007\/s00018-016-2407-7","journal-title":"Cell Mol Life Sci"},{"key":"4361_CR17","doi-asserted-by":"publisher","first-page":"967","DOI":"10.14336\/AD.2019.0901","volume":"11","author":"T Li","year":"2020","unstructured":"Li T, Mu N, Yin Y et al (2020) Targeting AMP-activated protein kinase in aging-related cardiovascular diseases. Aging Dis 11:967\u2013977. https:\/\/doi.org\/10.14336\/AD.2019.0901","journal-title":"Aging Dis"},{"key":"4361_CR18","doi-asserted-by":"publisher","first-page":"829","DOI":"10.2147\/DDDT.S443107","volume":"18","author":"J Li","year":"2024","unstructured":"Li J, Zhang L, Ge T et al (2024) Understanding sorafenib-induced cardiovascular toxicity: mechanisms and treatment implications. Drug des Devel Ther 18:829\u2013843. https:\/\/doi.org\/10.2147\/DDDT.S443107","journal-title":"Drug des Devel Ther"},{"key":"4361_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2025.07.030","author":"YG Park","year":"2025","unstructured":"Park YG, Park NK, Lee Y et al (2025) A machine learning platform for genotype-specific cardiotoxicity risk prediction using patient-derived iPSC-CMs. J Adv Res. https:\/\/doi.org\/10.1016\/j.jare.2025.07.030","journal-title":"J Adv Res"},{"key":"4361_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12872-024-03967-z","volume":"24","author":"R Qianqian","year":"2024","unstructured":"Qianqian R, Peng Z, Licai Z et al (2024) A longitudinal evaluation of oxidative stress - mitochondrial dysfunction - ferroptosis genes in anthracycline-induced cardiotoxicity. BMC Cardiovasc Disord 24:1\u201315. https:\/\/doi.org\/10.1186\/s12872-024-03967-z","journal-title":"BMC Cardiovasc Disord"},{"key":"4361_CR21","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1200\/JCO.1998.16.11.3502","volume":"16","author":"M Ryberg","year":"1998","unstructured":"Ryberg M, Nielsen D, Skovsgaard T et al (1998) Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 16:3502\u20133508. https:\/\/doi.org\/10.1200\/JCO.1998.16.11.3502","journal-title":"J Clin Oncol"},{"key":"4361_CR22","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1111\/bph.13577","volume":"174","author":"L Sala","year":"2017","unstructured":"Sala L, Bellin M, Mummery CL (2017) Integrating cardiomyocytes from human pluripotent stem cells in safety pharmacology: has the time come? Br J Pharmacol 174:3749\u20133765. https:\/\/doi.org\/10.1111\/bph.13577","journal-title":"Br J Pharmacol"},{"key":"4361_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1530\/EJE-13-0015","volume":"168","author":"RS Scheffel","year":"2013","unstructured":"Scheffel RS, Dora JM, Siqueira DR et al (2013) Toxic cardiomyopathy leading to fatal acute cardiac failure related to vandetanib: a case report with histopathological analysis. Eur J Endocrinol 168:51\u201354. https:\/\/doi.org\/10.1530\/EJE-13-0015","journal-title":"Eur J Endocrinol"},{"key":"4361_CR24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.stem.2022.12.002","volume":"30","author":"R Serrano","year":"2023","unstructured":"Serrano R, Feyen DAM, Bruyneel AAN et al (2023) A deep learning platform to assess drug proarrhythmia risk. Cell Stem Cell 30:86-95.e4. https:\/\/doi.org\/10.1016\/j.stem.2022.12.002","journal-title":"Cell Stem Cell"},{"key":"4361_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/scrt380","volume":"4","author":"A Sharma","year":"2013","unstructured":"Sharma A, Wu JC, Wu SM (2013) Induced pluripotent stem cell-derived cardiomyocytes for cardiovascular disease modeling and drug screening. Stem Cell Res Ther 4:150. https:\/\/doi.org\/10.1186\/scrt380","journal-title":"Stem Cell Res Ther"},{"key":"4361_CR26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1177\/2168479018795117","volume":"53","author":"DG Strauss","year":"2019","unstructured":"Strauss DG, Gintant G, Li Z et al (2019) Comprehensive in vitro proarrhythmia assay (CiPA) update from a cardiac safety research consortium\/health and environmental sciences institute\/FDA meeting. Ther Innov Regul Sci 53:519\u2013525. https:\/\/doi.org\/10.1177\/2168479018795117","journal-title":"Ther Innov Regul Sci"},{"key":"4361_CR27","doi-asserted-by":"publisher","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","volume":"91","author":"DD von Hoff","year":"1979","unstructured":"von Hoff DD, Layard MW, Basa P et al (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710\u2013717. https:\/\/doi.org\/10.7326\/0003-4819-91-5-710","journal-title":"Ann Intern Med"},{"key":"4361_CR28","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1016\/j.jtho.2021.07.030","volume":"16","author":"S Waliany","year":"2021","unstructured":"Waliany S, Zhu H, Wakelee H et al (2021) Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic NSCLC. J Thorac Oncol 16:2029\u20132039. https:\/\/doi.org\/10.1016\/j.jtho.2021.07.030","journal-title":"J Thorac Oncol"},{"key":"4361_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030353","author":"J Zang","year":"2012","unstructured":"Zang J, Wu S, Tang L et al (2012) Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0030353","journal-title":"PLoS ONE"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-026-04361-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-026-04361-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-026-04361-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T18:35:01Z","timestamp":1784313301000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-026-04361-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4361"],"URL":"https:\/\/doi.org\/10.1007\/s00204-026-04361-8","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The manuscript does not contain newly generated clinical studies or patient data.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work, the author used Google Gemini to get assistance for generating experimental schematic diagrams in Figs.\n                      \n                      a,\n                      \n                      a, and\n                      \n                      a, and the images generated by the tool based on author\u2019s prompt. After using this tool, the author reviewed and edited the content as needed and takes full responsibility for the content of the published article.","order":3,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the manuscript preparation process","group":{"name":"EthicsHeading","label":"Declarations"}}]}}